Condition

Advanced Solid Tumors clinical trials and research

• 205Clinical trials
• 1New in 30 days
• 43Countries

Newest Advanced Solid Tumors clinical trials

All recruiting trials (newest 150 of 205)

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• AK157D1 injection for advanced solid tumors

  A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.

  Recruiting Phase 1 Akeso · Harbin, Heilongjiang and 2 other locations · NCT07847281

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• MK-2010 alone or with other treatments for advanced solid tumors

  This trial tests MK-2010, by itself or with other cancer medicines, to see if it helps people with advanced solid tumors.

  Recruiting at 7 sites Phase 2 Merck Sharp & Dohme LLC · Belleville, New Jersey and 6 other locations · NCT07793942

• Whole-Body Infrared Heating for Advanced Solid Tumors

  This study looks at how ET-SPACE whole-body infrared hyperthermia affects people with advanced solid tumors to see if it changes biology, symptoms, and safety.

  Recruiting Zhejiang Hospital · Hangzhou, Zhejiang · NCT07793214

• MK-2010 with Sac-TMT in advanced solid tumors

  This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.

  Recruiting at 4 sites Phase 2 Merck Sharp & Dohme LLC · San Antonio, Texas and 3 other locations · NCT07785609

• CBX-663 dose-escalation study in adults with relapsed or refractory myeloid cancers, advanced solid tumors, or glioblastoma

  This early-phase trial tests CBX-663 to see if it is safe and tolerable and to get an early sense of activity in adults with relapsed/refractory myeloid cancers, advanced solid tumors, or recurrent glioblastoma.

  Recruiting at 4 sites Phase 1 Crossbow Therapeutics, Inc. · Duarte, California and 3 other locations · NCT07779798

• HS-20117-2 Injection in Patients With Advanced Solid Tumors (Phase 1)

  This phase 1 study tests HS-20117-2 given under the skin to see how the drug behaves in the body and whether it’s safe for adults with advanced solid tumors.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Guangzhou, Guangdong · NCT07775703

• ATX-898 in people with advanced solid tumors

  This study tests ATX-898 by itself and with other cancer drugs in adults with advanced solid tumors to see if it is safe and potentially effective.

  Recruiting at 6 sites Phase 1/2 Antares Therapeutics, Inc · Fort Worth, Texas and 5 other locations · NCT07767474

• SM2275 Injection in Advanced Solid Tumors

  A first-in-human study tests SM2275 to see if it is safe and tolerable and to get a sense of any anti-tumor activity in adults with advanced solid tumors that progressed after standard therapy.

  Recruiting Phase 1 Beijing StarMab Biomed Technology Ltd · Beijing · NCT07750132

• SYS6041: a first-in-human test in adults with advanced solid tumors

  This first-in-human trial tests SYS6041 in adults with advanced solid tumors to see if it is safe, how it behaves in the body, and whether it shows any signs of shrinking tumors.

  Recruiting Phase 1/2 CSPC Megalith Biopharmaceutical Co.,Ltd. · Shanghai, Shanghai Municipality · NCT07744763

• HW221043 in people with advanced solid tumors

  This phase 1 study tests HW221043 tablets to see if they are safe and tolerable in adults with advanced solid tumors who have few or no good treatment options.

  Recruiting Phase 1 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Shanghai, Shanghai Municipality · NCT07719920

• PA5 in adults with advanced solid tumors

  This trial tests PA5 as a single-drug treatment to see if it is safe and tolerable for adults with advanced solid tumors and to find an appropriate dose for future studies.

  Recruiting at 2 sites Phase 1 Chongqing Peg-Bio Biopharm Co., Ltd. · Fuzhou, Fujian and 1 other locations · NCT07702162

• First-in-Human Trial of a VBC108 Treatment for Advanced Solid Tumors

  This early-stage trial tests VBC108 in adults with unresectable or metastatic solid tumors to see if it is safe and tolerable and to get a sense of how well it might work.

  Recruiting at 5 sites Phase 1/2 VelaVigo Bio Inc · Duarte, California and 11 other locations · NCT07700160

• OVV-01: a first-in-human test to treat advanced solid tumors with IV and injected therapy

  This early-phase study tests OVV-01 given by IV and direct tumor injection in adults with advanced solid tumors to see if it’s safe and can show signals of activity.

  Recruiting Phase 1 Joint Biosciences Ltd. · Beijing, Beijing Municipality · NCT07648472

• CS5007 in people with advanced solid tumors

  This first-in-human study tests CS5007 as a single treatment to see if it is safe and tolerable in adults with unresectable advanced solid tumors and a measurable lesion.

  Recruiting at 4 sites Phase 1 CStone Pharmaceuticals · Darlinghurst, New South Wales and 6 other locations · NCT07622524

• HF50 safety and activity in advanced solid tumors

  This study tests HF50, a targeted therapy, to see if it is safe and can help people with advanced solid tumors.

  Recruiting Phase 1 HighField Biopharmaceuticals Corporation · Beijing, Beijing Municipality and 1 other locations · NCT07601334

• GS-2426 in MTAP-deleted advanced solid tumors

  This study tests whether GS-2426 is safe and tolerable in adults with MTAP-deleted advanced solid tumors to help find a suitable dose for further testing.

  Recruiting at 6 sites Phase 1 Gilead Sciences · Boston, Massachusetts and 5 other locations · NCT07601243

• KXV01 Injection for Advanced Solid Tumors

  A single-arm, early-stage test to see if KXV01 TCR Lentinvivo is safe and tolerable and to get a first look at any signs it might help patients with advanced solid tumors.

  Recruiting Phase 1 TCRx Therapeutics Co.Ltd · Shanghai · NCT07596693

• TROP2-targeted CAR-NK cell therapy for advanced solid tumors

  This study tests EB-NK-301, an off-the-shelf CAR-NK cell therapy, in adults with advanced or metastatic TROP2-expressing solid tumors after standard treatments have failed.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07589530

• SKB118 Injection in Advanced Solid Tumors (Part 1: monotherapy; Part 2: in combination with SKB264)

  This study tests SKB118 alone and in combination with SKB264 to see if it is safe and can help people with advanced solid tumors who have few or no other options.

  Recruiting Phase 1/2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07586943

• Intratumoral injection of mechanically reprogrammed macrophage-derived exosomes for advanced solid tumors

  This trial will test whether injecting mechanically reprogrammed macrophage-derived exosomes directly into tumors is safe and tolerable in adults 18–65 with advanced solid tumors who have no standard treatment options.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07563972

• NK521 for malignant ascites from advanced solid tumors

  This trial will test NK521, an NK-cell therapy, in adults (18–75) with relapsed or refractory advanced solid tumors and cytology-confirmed malignant ascites who have failed at least two standard treatments.

  Recruiting Early Phase 1 Base Therapeutics (Shanghai) Co., Ltd. · Beijing, Beijing Municipality · NCT07561437

• Allogeneic WTX-212C in Advanced Solid Tumors

  This early-phase study tests whether an allogeneic engineered red blood cell product, WTX-212C, is safe and may help people with advanced solid tumors who have few or no good treatment options.

  Recruiting Early Phase 1 Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT07556653

• SKB565 injection for advanced solid tumors

  This phase 1/2 study tests SKB565 in adults with advanced solid tumors who have exhausted or cannot tolerate standard therapies.

  Recruiting at 2 sites Phase 1/2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07545265

• KQB368 as a single-drug treatment for adults with advanced solid tumors

  This study tests whether taking KQB368 by mouth every day can help shrink tumors and is safe for adults with advanced solid cancers.

  Recruiting at 14 sites Phase 1 Kumquat Biosciences Inc. · Los Angeles, California and 13 other locations · NCT07542704

• HDM2024 for people with advanced solid tumors

  This trial will test HDM2024 to see if it's safe and can shrink tumors in adults with advanced solid cancers who have progressed after or cannot tolerate standard treatments.

  Recruiting Phase 1 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07539285

• E303 safety in people with advanced refractory solid tumors

  This Phase I trial will test whether the drug E303 is safe and tolerable in people with advanced solid tumors who have not responded to or cannot receive standard treatments.

  Recruiting at 7 sites Phase 1 Samsung Bioepis Co., Ltd. · Scottsdale, Arizona and 6 other locations · NCT07524348

• FL-261 imaging to detect and stage c-MET–expressing cancers

  This first-in-human test uses FL-261 labeled for PET or SPECT to see if it safely highlights c-MET–positive tumors in adults with advanced solid tumors such as non-small cell lung, colorectal, or head and neck cancer.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07510321

• Claudin 18.2-targeted therapy LCB02A in advanced solid tumors

  This study tests LCB02A in adults with advanced solid tumors that express Claudin 18.2 and have few or no standard treatment options left.

  Recruiting at 2 sites Phase 1/2 LigaChem Biosciences, Inc. · Boston, Massachusetts and 7 other locations · NCT07460375

• SKB103 injection for advanced solid tumors

  This study tests a SKB103 injection to see if it is safe and effective for adults with advanced solid tumors who have limited treatment options.

  Recruiting at 2 sites Phase 1/2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Harbin, Heilongjiang and 1 other locations · NCT07459998

• Hemay181 for advanced solid tumors

  This trial will try the experimental drug Hemay181 in people with advanced solid tumors who have not responded to standard treatments.

  Recruiting Phase 1 Ganzhou Hemay Pharmaceutical Co., Ltd · Xinxiang, Henan · NCT07446816

• First-in-human test of CKD-703 for advanced solid tumors and non-small cell lung cancer

  This trial will test CKD-703, a targeted antibody–drug conjugate, in adults with advanced c‑Met–expressing solid tumors and in MET‑amplified or c‑Met–overexpressing non‑small cell lung cancer who have exhausted standard treatments.

  Recruiting Phase 1/2 Chong Kun Dang Pharmaceutical · Ohio City, Ohio · NCT07439094

• BPI-572270 in RAS-mutant advanced solid tumors (including NSCLC, CRC, PDAC)

  This study tests whether BPI-572270 is safe and tolerable in adults with RAS-mutant advanced solid tumors and looks for signs of clinical activity.

  Recruiting Phase 1/2 Betta Pharmaceuticals Co., Ltd. · Blacktown, New South Wales and 6 other locations · NCT07435038

• GK01 cell injections for advanced lung and esophageal squamous cell cancers

  This study tests whether injections of GK01 cells are safe and can shrink tumors or slow growth in people with advanced lung cancer or esophageal squamous cell carcinoma who no longer respond to standard treatments.

  Recruiting Early Phase 1 Beijing Geekgene Technology Co., LTD · Nanchang · NCT07414316

• HWS116 as a single treatment for advanced solid tumors

  This Phase 1 trial will try HWS116 as a single treatment in adults with advanced solid tumors to see if it's safe, how the body handles it, and whether it helps tumors.

  Recruiting Phase 1 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company · Guangzhou, Guangdong · NCT07413328

• Combining RAS(ON) inhibitors with ivonescimab for adults with RAS‑mutant advanced solid tumors

  This trial will test whether combining RAS(ON) inhibitors with ivonescimab is safe and can shrink or control tumors in adults with advanced or metastatic solid tumors that have RAS mutations.

  Recruiting at 19 sites Phase 1/2 Revolution Medicines, Inc. · Scottsdale, Arizona and 18 other locations · NCT07397338

• GEN1079 treatment for advanced solid tumors

  This trial will test whether the antibody GEN1079 is safe and can help people with advanced solid tumors.

  Recruiting at 12 sites Phase 1 Genmab · New Haven, Connecticut and 11 other locations · NCT07387068

• SKB105 injection for advanced solid tumors

  This Phase 1/2 trial will try SKB105 in adults with advanced solid tumors to see if it is safe, well tolerated, and can slow or shrink tumors.

  Recruiting Phase 1/2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07380386

• Testing HDM2006 in adults with advanced solid tumors

  This will test a new medicine called HDM2006 to see if it is safe and can help adults with advanced or metastatic solid tumors who have run out of standard treatment options.

  Recruiting Phase 1 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Shanghai · NCT07377591

• Rezatapopt's effect on common drug levels in people with advanced solid tumors carrying the TP53 Y220C mutation.

  This test sees if rezatapopt changes how common drugs—metformin, rosuvastatin, repaglinide, and midazolam—are processed in people with advanced solid tumors that carry the TP53 Y220C mutation.

  Recruiting at 5 sites Phase 1 PMV Pharmaceuticals, Inc · Denver, Colorado and 4 other locations · NCT07372625

• M7437 (anti-Ly6E exatecan antibody–drug conjugate) for advanced solid tumors with Ly6E expression

  This trial will test M7437, an antibody–drug conjugate that targets Ly6E and delivers a topoisomerase I inhibitor, to see if it is safe and helps people with advanced solid tumors that express Ly6E.

  Recruiting at 7 sites Phase 1 EMD Serono · New Haven, Connecticut and 8 other locations · NCT07360314

• SPR1020, a new selective PARP1 drug for adults with advanced solid tumors.

  This study will test SPR1020, a highly selective PARP1 inhibitor, in adults with advanced solid tumors—especially cancers with BRCA or other homologous recombination deficiency (HRD) mutations—to find safe doses and look for early signs of benefit.

  Recruiting at 13 sites Phase 1/2 Shanghai SciBrunch Therapeutics Co., Ltd. · Hefei, Anhui and 12 other locations · NCT07359066

• FORX-428 for advanced solid tumors with BRCA or other DNA repair defects

  This trial will test whether the drug FORX-428 is safe and shows activity in adults with advanced solid tumors that have BRCA1/2 mutations or other DNA damage repair problems.

  Recruiting at 8 sites Phase 1 FoRx Therapeutics AG · Palo Alto, California and 7 other locations · NCT07356453

• RMC-5127 for advanced cancers with KRAS G12V mutation

  This trial will test whether the experimental drug RMC-5127, alone or with daraxonrasib or cetuximab, helps adults with advanced KRAS G12V-mutant solid tumors.

  Recruiting at 9 sites Phase 1 Revolution Medicines, Inc. · New Haven, Connecticut and 8 other locations · NCT07349537

• Metabolically armed tumor-infiltrating lymphocytes (Meta10-TIL) treatment for advanced solid tumors

  This study will try Meta10-TIL — immune cells taken from your tumor, metabolically modified and given back — to see if it is safe and helps people with advanced solid tumors who have exhausted standard options.

  Recruiting Early Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07349160

• BGM-2121 for adults with advanced solid tumors

  This tests whether BGM-2121 is safe and may help adults whose advanced solid tumors have not responded to standard treatments.

  Recruiting Phase 1 BioGate Precision Medicine Corp. · Tainan and 2 other locations · NCT07346846

• GW5282 treatment for adults with advanced solid tumors

  This trial will test GW5282 to see if it's safe, how it's processed in the body, and whether it helps adults with locally advanced or metastatic solid tumors who have finished standard treatments.

  Recruiting at 3 sites Phase 1/2 Dizal Pharmaceuticals · Beijing, Beijing Municipality and 2 other locations · NCT07328217

• ABP1011T tablets for people with advanced solid tumors, including small cell lung cancer

  This trial will test whether taking ABP1011T tablets daily can help people with advanced solid tumors, especially those with small cell lung cancer who have already had other treatments.

  Recruiting at 3 sites Phase 2 Shanghai AB PharmaTech Ltd. · Luoyang, Henan and 7 other locations · NCT07321574

• ZX-8177 treatment for adults with advanced solid tumors

  This trial will test whether taking ZX-8177 twice daily is safe and tolerable for adults with advanced solid tumors who have no standard treatment options left.

  Recruiting Phase 1 Nanjing Zenshine Pharmaceuticals · Shanghai · NCT07310134

• AT1019 injections with focused radiation and PD-1 immunotherapy for advanced solid tumors

  This will test whether giving injected AT1019 together with focused radiation (SBRT) and a PD‑1 immunotherapy is safe and tolerable for adults with advanced solid tumors.

  Recruiting Phase 1 The Affiliated Hospital of Xuzhou Medical University · Xuzhou, Jiangsu · NCT07285395

• Personalized KXV01 TCR Lentivivo Injection for Advanced Solid Tumors

  A single-center, early-phase study will test a personalized T cell therapy delivered in vivo to see if it is safe and may help people with advanced solid tumors who have exhausted other options.

  Recruiting Phase 1 TCRx Therapeutics Co.Ltd · Beijing · NCT07275853

• OTP-01 (dual PD-1/VEGFR2 antibody) for advanced solid tumors

  This trial tests whether OTP-01, an antibody that targets PD‑1 and VEGFR2, is safe, tolerable, and can shrink tumors in adults with advanced solid tumors.

  Recruiting at 23 sites Phase 1/2 Ottimo Pharma Limited · New Haven, Connecticut and 22 other locations · NCT07266428

• BTM-3566 for advanced solid tumors

  This phase 1 trial will test if BTM-3566 is safe and can shrink or slow advanced solid tumors in adults who have exhausted standard treatments.

  Recruiting at 2 sites Phase 1 Bantam Pharmaceuticals · Houston, Texas and 1 other locations · NCT07266285

• EIK1005 (Werner helicase inhibitor) alone or with pembrolizumab for advanced MSI-H/dMMR and other solid tumors

  This trial tests whether EIK1005, given alone or together with pembrolizumab, can be safely given and help people with advanced solid tumors, especially MSI‑H/dMMR cancers.

  Recruiting at 44 sites Phase 1/2 Eikon Therapeutics · Los Angeles, California and 44 other locations · NCT07262619

• WJ22096 tablets for adults with advanced solid tumors

  This Phase I/II trial will test whether WJ22096 tablets are safe and might help adults with advanced solid tumors who have no standard treatment options.

  Recruiting Phase 1/2 Nanjing Jingao biomidical technology Co. Ltd. · Beijing, Beijing Municipality · NCT07253116

• GenSci143 for advanced solid tumors

  This trial will test whether the experimental drug GenSci143 is safe and can shrink or slow tumors in adults with advanced solid cancers who have exhausted or cannot tolerate standard treatments.

  Recruiting at 9 sites Phase 1 Changchun GeneScience Pharmaceutical Co., Ltd. · Los Angeles, California and 12 other locations · NCT07252414

• GenSci140 for advanced solid tumors

  This Phase 1 test will try GenSci140 to see if it is safe and shows early signs of benefit in adults with advanced solid tumors, including FRα-positive ovarian cancer.

  Recruiting Phase 1 Changchun GeneScience Pharmaceutical Co., Ltd. · Shenyang, Liaoning · NCT07251166

• Albumin-bound sirolimus combined with different antibody-drug conjugates for advanced solid tumors

  This trial will try giving albumin-bound sirolimus together with various antibody-drug conjugates to people with advanced solid tumors to see if the combinations are safe and show anticancer activity.

  Recruiting Phase 1/2 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Shanghai · NCT07241936

• ABX-001 alone or with pembrolizumab for advanced solid tumors

  This tests whether the new immunotherapy ABX-001, given alone or with pembrolizumab, is safe and shows signs of benefit in adults with advanced solid tumors that have stopped responding to prior treatments.

  Recruiting at 5 sites Phase 1 Abalos Therapeutics GmbH · Berlin and 4 other locations · NCT07231458

• GenSci139 for adults with advanced solid tumors

  This study will try GenSci139 in adults with locally advanced or metastatic solid tumors to see if it is safe and can slow or shrink tumors.

  Recruiting Phase 1 Changchun GeneScience Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07230977

• GEN-725 tablets for adults with advanced solid tumors

  This phase 1 study will test whether GEN-725 tablets are safe, how the body handles them, and whether they might help adults whose advanced solid tumors have not responded to standard treatments.

  Recruiting at 4 sites Phase 1 Henan Genuine Biotech Co., Ltd. · Harbin and 3 other locations · NCT07229898

• VIB305 safety testing in advanced solid tumors.

  This trial will test whether VIB305 is safe and tolerable for adults with unresectable advanced solid tumors who have exhausted, are intolerant of, or have declined standard treatments.

  Recruiting at 2 sites Phase 1/2 Vibrant Sciences Limited · Sunshine Coast and 1 other locations · NCT07222969

• CKD-512 alone and with pembrolizumab for advanced or metastatic solid tumors

  This study will try CKD-512 by itself and together with pembrolizumab in people with advanced or metastatic solid tumors who have exhausted standard treatments.

  Recruiting Phase 1 Chong Kun Dang Pharmaceutical · Seoul · NCT07215637

• LY4337713 for people with FAP-positive ovarian, breast, pancreatic, colorectal, or esophageal cancers

  This trial tests LY4337713, a FAP-targeted lutetium-177 therapy, in people with advanced cancers that show high levels of fibroblast activation protein (FAP).

  Recruiting at 17 sites Phase 1 Eli Lilly and Company · Newport Beach, California and 29 other locations · NCT07213791

• Combination of YL201 and ivonescimab (AK112) for advanced solid tumors

  This trial will test whether combining YL201 and ivonescimab (AK112) helps people with advanced solid tumors, including non‑small cell and small cell lung cancer.

  Recruiting Phase 1/2 MediLink Therapeutics (Suzhou) Co., Ltd. · Guangzhou, Guangdong · NCT07208773

• JMKX005425 for people with MSI‑H or dMMR advanced solid tumors

  This trial will try JMKX005425 in people with MSI‑H or dMMR advanced solid tumors to see if it is safe, well tolerated, how the body processes it, and whether it shows early signs of benefit.

  Recruiting Phase 1 Jemincare · Beijing · NCT07208136

• ST-01156, a drug that degrades RBM39, for advanced solid cancers

  This trial will test whether ST-01156 is safe and shows early anti-cancer activity in adults (and some teens with Ewing sarcoma) who have advanced or metastatic solid tumors like liver, biliary tract, or Ewing sarcoma.

  Recruiting at 6 sites Phase 1 SEED Therapeutics, Inc. · Duarte, California and 5 other locations · NCT07197554

• How itraconazole affects HS-20093 levels in people with advanced solid tumors

  This test will see if taking oral itraconazole changes how the experimental cancer drug HS-20093 is processed in people with advanced solid tumors who have not responded to standard treatments.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Changsha, Hunan · NCT07186452

• Oncolytic vaccinia virus (hV01) plus PD-1 drug tislelizumab for advanced solid tumors

  This trial will test whether adding an IL-21–expressing oncolytic vaccinia virus (hV01) to the PD‑1 drug tislelizumab is safe and can shrink tumors in adults with advanced solid cancers that no longer respond to standard treatments.

  Recruiting Hangzhou Converd Co., Ltd. · Xiamen, Fujian · NCT07185243

• Continuing sotorasib with or without panitumumab for adults with KRAS p.G12C advanced solid tumors

  This trial tries continuing sotorasib, with or without panitumumab, in adults with KRAS p.G12C advanced solid tumors who are already benefiting from an Amgen trial to see if ongoing treatment remains safe and tolerable.

  Recruiting at 9 sites Phase 2 Amgen · Fort Myers, Florida and 10 other locations · NCT07172919

• YL202 combined with immunotherapy or targeted therapy for advanced solid tumors

  This trial tests whether adding YL202 to other anti-tumor treatments helps adults with advanced solid tumors (including breast cancer and non‑small cell lung cancer) tolerate therapy and control tumor growth.

  Recruiting Phase 1/2 MediLink Therapeutics (Suzhou) Co., Ltd. · Hefei, Anhui and 19 other locations · NCT07169994

• Compression stockings to prevent peripheral neuropathy in patients receiving MMAE-containing ADCs for urothelial cancer

  This study will test whether wearing a medical compression stocking on one foot during antibody–drug conjugate (MMAE-containing) infusions can prevent peripheral neuropathy in adults with advanced urothelial carcinoma or other cancers.

  Recruiting Fudan University · Shanghai · NCT07164950

• Subcutaneous rilvegostomig with hyaluronidase for adults with advanced solid tumors

  This trial will test whether subcutaneous rilvegostomig given with recombinant human hyaluronidase produces drug levels similar to the intravenous form in adults with advanced solid tumors who have already received standard treatments and are suitable for immuno-oncology monotherapy.

  Recruiting at 8 sites Phase 1 AstraZeneca · Huntersville, North Carolina and 10 other locations · NCT07161414

• SYN818 plus olaparib for advanced or metastatic BRCA‑mutant or HRD solid tumors

  This study tests whether combining SYN818 with olaparib is safe and helps control advanced or metastatic solid tumors in adults whose cancers have BRCA mutations or homologous recombination repair defects.

  Recruiting at 2 sites Phase 1 Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Shanghai, Shanghai Municipality and 1 other locations · NCT07156253

• WEF-001 for advanced KRAS‑mutant solid tumors

  This trial will try WEF-001 alone in people with advanced KRAS‑mutant solid tumors (such as pancreatic, colorectal, or non‑small cell lung cancer) to check safety, dosing, and early signs it can shrink tumors.

  Recruiting at 4 sites Phase 1/2 Auricula Biosciences Inc. · Dallas, Texas and 3 other locations · NCT07148128

• FL115 combined with a PD-1 antibody for advanced solid tumors

  This study will test whether giving FL115 together with the PD‑1 antibody sintilimab is safe and can help shrink tumors in people with advanced solid tumors.

  Recruiting Phase 1/2 Suzhou Forlong Biotechnology Co., Ltd · Guangzhou, Guangdong · NCT07131202

• PHN-012 for people with advanced colon, lung (NSCLC), or pancreatic cancer.

  This trial will try PHN-012, a new antibody-drug conjugate, in people with advanced colon, non-small cell lung, or pancreatic cancer who have already received other treatments.

  Recruiting at 26 sites Phase 1 Pheon Therapeutics · Los Angeles, California and 25 other locations · NCT07127874

• Metabolically armed tumor‑infiltrating lymphocytes (Meta10‑TIL) therapy for advanced solid tumors

  This study will try giving Meta10‑TIL, specially prepared immune cells, to adults with advanced solid tumors to see if it's safe and can help control tumor growth.

  Recruiting Early Phase 1 Anhui Provincial Hospital · Hefei, Anhui · NCT07106814

• HDM2012 for advanced solid tumors

  This first-in-human study will try HDM2012, an experimental drug, in adults with advanced solid tumors to check safety and early signs of benefit.

  Recruiting Phase 1 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Shanghai · NCT07100249

• MRG006A treatment for advanced solid tumors

  This will test whether the antibody–drug conjugate MRG006A is safe and can help adults with advanced solid tumors.

  Recruiting at 2 sites Phase 1/2 Lepu Biopharma Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07093970

• Safety and drug-level testing of BMS-986504 for advanced solid tumors with MTAP deletion

  This trial tests whether BMS-986504 is safe, tolerable, and reaches acceptable drug levels in adults with advanced solid tumors that have an MTAP gene deletion.

  Recruiting at 12 sites Phase 1 Bristol-Myers Squibb · Beijing, Beijing Municipality and 11 other locations · NCT07077434

• AK146D1 injection for advanced solid tumors.

  This will test whether AK146D1 injection is safe and shows early anti-tumor activity in adults with advanced solid tumors who have progressed on or cannot receive standard treatments.

  Recruiting Phase 1 Akeso · Guangzhou, Guangdong · NCT07067567

• NTS071 safety and early effectiveness in TP53 Y220C-mutated advanced solid tumors

  This study tests NTS071 in adults with TP53 Y220C-mutated advanced solid tumors to see if it is safe and tolerable and if there are signs of activity.

  Recruiting at 9 sites Phase 1/2 Nutshell Therapeutics (Shanghai) Co., LTD. · New Haven, Connecticut and 9 other locations · NCT07060989

• Cisplatin plus gemcitabine for adults after PD‑1 therapy failure or with certain rare advanced tumors

  This study will test whether the chemotherapy combination cisplatin plus gemcitabine can shrink advanced solid tumors in adults whose cancer progressed after PD‑1 therapy or who have certain rare aggressive tumors.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07046650

• Safety and tolerability of SBO-154 for people with advanced solid tumors

  This trial tests whether the experimental drug SBO-154 is safe and tolerable for adults with advanced solid tumors who have not responded to or cannot take standard treatments.

  Recruiting at 12 sites Phase 1 Sun Pharma Advanced Research Company Limited · Scottsdale, Arizona and 15 other locations · NCT07042100

• Pralatrexate dosing and safety in adults with cancer and differing liver function

  This trial will test how pralatrexate is processed by the body and what doses are safe for adults with advanced solid tumors or blood cancers who have normal or impaired liver function.

  Recruiting at 3 sites Phase 1 Acrotech Biopharma Inc. · Cerritos, California and 3 other locations · NCT07036133

• CM518D1 treatment for advanced solid tumors

  This trial will test CM518D1 to see if it is safe, tolerable, and can help adults with advanced solid tumors.

  Recruiting Phase 1/2 Keymed Biosciences Co.Ltd · Guangzhou, Guangdong · NCT07019779

• HDM2005 for advanced solid tumors

  This trial will test whether HDM2005 is safe and has anti-tumor activity in adults with metastatic solid tumors that have progressed after prior treatments.

  Recruiting Phase 1 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07004296

• HBT-708 for people with advanced solid tumors

  This trial will test whether HBT-708 given intravenously every three weeks is safe, tolerable, and might help people with advanced solid tumors.

  Recruiting Phase 1 Shenyang Sunshine Pharmaceutical Co., LTD. · Shanghai, Shanghai Municipality · NCT06993870

• ETX-636 treatment for advanced PIK3CA-mutant solid tumors and HR+ HER2- breast cancer

  This will test ETX-636 alone and together with fulvestrant in people with advanced solid tumors that have a PIK3CA mutation, including HR+, HER2- breast cancer.

  Recruiting at 15 sites Phase 1/2 Ensem Therapeutics · Newport Beach, California and 14 other locations · NCT06993844

• FP008 treatment for adults with advanced solid tumors

  This phase 1 trial will test FP008 to see if it is safe and shows signs of antitumor activity in adults with advanced solid tumors.

  Recruiting at 6 sites Phase 1 Zhuhai Fapon Biopharma Co., Ltd. · Guangzhou, Guangdong and 5 other locations · NCT06990698

• SIBP-A19 injection for advanced solid tumors

  This will test SIBP-A19 injection in adults with advanced solid tumors to find a safe dose and see side effects and how the drug behaves in the body.

  Recruiting Phase 1 Shanghai Institute Of Biological Products · Fuzhou, Fujian · NCT06990464

• JAB-23E73 treatment for adults with advanced solid tumors that have KRAS changes

  This trial will try JAB-23E73, an oral pan-KRAS drug, to see if it is safe and helps adults with advanced solid tumors that carry KRAS mutations.

  Recruiting at 4 sites Phase 1/2 Jacobio Pharmaceuticals Co., Ltd. · Rochester, Minnesota and 3 other locations · NCT06973564

• Testing HSK41959 in patients with advanced solid tumors and MTAP deletion

  This study is testing a new oral medication called HSK41959 to see if it is safe and tolerable for patients with advanced solid tumors that have a specific gene deletion.

  Recruiting at 2 sites Phase 1 Haisco Pharmaceutical Group Co., Ltd. · Guiyang, Guizhou and 2 other locations · NCT06968572

• Evaluating TGW101 for advanced solid tumors

  This study is testing a new drug called TGW101 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 7 sites Phase 1 Tagworks Pharmaceuticals BV · Scottsdale, Arizona and 6 other locations · NCT06959706

• Testing GK01 for advanced solid tumors

  This study is testing a new treatment called GK01 to see if it can help people with advanced solid tumors who haven't had success with other therapies.

  Recruiting Phase 1 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT06954558

• AK129 combination therapy for advanced solid tumors

  This study tests AK129 given with chemotherapy in adults with advanced non-small cell lung, head and neck, or colorectal cancers to find a safe dose and see if it helps control their disease.

  Recruiting Phase 1/2 Akeso · Shenyang, Liaoning · NCT06943820

• AK146D1 injection for adults with advanced solid tumors

  This trial will try an experimental injection called AK146D1 in adults with advanced solid tumors that have progressed after standard treatment.

  Recruiting Phase 1 Akeso · Sydney, New South Wales · NCT06929663

• HS-20122 for adults with advanced solid tumors

  This first-in-human Phase I test will try HS-20122 in adults with advanced solid tumors to find safe dosing, watch for side effects, and look for early signs it helps control tumors.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Guangzhou, Guangdong · NCT06927570

• Evaluating HRS-6768 for advanced solid tumors

  This study is testing a new drug called HRS-6768 to see if it can help people with advanced solid tumors who haven't had success with other treatments.

  Recruiting at 2 sites Phase 1/2 Jiangsu HengRui Medicine Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT06925581

• Evaluating TYRA-430 for advanced liver and solid tumors with specific genetic changes

  This study is testing a new drug called TYRA-430 to see if it can help people with advanced liver and other solid tumors that have certain genetic changes.

  Recruiting at 15 sites Phase 1 Tyra Biosciences, Inc · Los Angeles, California and 15 other locations · NCT06915753

• Evaluating SHR-3792 Injection for Advanced Solid Tumors

  This study is testing a new injection called SHR-3792 to see if it can safely help people with advanced solid tumors feel better and how much of it they should take.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Jinan, Shandong · NCT06907628

• Evaluating EIK1004 for Advanced Solid Tumors

  This study is testing a new drug called EIK1004 to see if it is safe and effective for people with advanced solid tumors like breast, ovarian, prostate, and pancreatic cancers who have certain genetic mutations.

  Recruiting at 10 sites Phase 1/2 Eikon Therapeutics · Denver, Colorado and 9 other locations · NCT06907043

• Testing SHR-A2102 with other cancer treatments for advanced solid tumors

  This study is testing a new cancer treatment called SHR-A2102 combined with other therapies to see if it helps people with advanced solid tumors feel better and improve their outcomes.

  Recruiting Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Taiyuan, Shanxi · NCT06895928

• First-in-human YB1-X7 injection for advanced solid tumors

  This trial tests YB1-X7, an engineered Salmonella therapy, to see if it is safe and tolerable in adults with advanced solid tumors that have failed standard treatments.

  Recruiting Shaoxing Salvectors Biotechnology LTD. · Langfang, Hebei · NCT06889675

• HW071021 monotherapy for advanced solid tumors

  This study will try an oral drug called HW071021 by itself to see if it is safe and helps adults with advanced solid tumors who have no standard treatment options.

  Recruiting Phase 1 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company · Guangzhou, Guangdong · NCT06882135

• Testing mRNA-4106 alone and with immune therapy for advanced solid tumors

  This study is testing a new treatment called mRNA-4106, both by itself and with other immune therapies, to see if it can help people with advanced solid tumors who have run out of other options or are newly diagnosed.

  Recruiting at 3 sites Phase 1 ModernaTX, Inc. · Los Angeles, California and 3 other locations · NCT06880549

• Testing PHST001 for advanced solid tumors

  This study is testing a new treatment called PHST001 to see if it is safe and effective for people with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 20 sites Phase 1 Pheast Therapeutics · Beverly Hills, California and 19 other locations · NCT06840886

• Evaluating MB0151 for advanced solid tumors with somatostatin receptors

  This study is testing a new treatment called MB0151 to see if it can help adults with advanced solid tumors that have specific receptors and who haven't had success with other treatments.

  Recruiting Phase 1/2 Mainline Biosciences (Shanghai) Co., Ltd · Jinan, Shandong · NCT06840821

• Investigating ALTA3263 for advanced solid tumors with KRAS mutations

  This study is testing a new oral medication called ALTA3263 to see if it is safe and effective for adults with advanced solid tumors that have KRAS mutations.

  Recruiting at 14 sites Phase 1 Alterome Therapeutics, Inc. · Orlando, Florida and 13 other locations · NCT06835569

• Evaluating FS-8002 for advanced solid tumors

  This study is testing a new treatment called FS-8002 to see if it is safe and effective for people with advanced solid tumors who have not responded to or cannot tolerate standard therapies.

  Recruiting at 10 sites Phase 1 Shanghai Pushi Medical Science Co. Ltd · Beijing, Beijing Municipality and 9 other locations · NCT06832982

• SKB445 injection for treating advanced solid tumors

  This study is testing a new injection called SKB445 to see if it can safely help people with advanced solid tumors.

  Recruiting Phase 1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Jinan, Shandong · NCT06826040

• HER2 antibody therapy using Lutetium-177 for advanced solid tumors

  This study is testing a new treatment using a special type of radiation for people with advanced solid tumors that are HER2 positive to see if it is safe and effective.

  Recruiting at 5 sites Early Phase 1 Radiopharm Theranostics, Ltd · Kingswood, New South Wales and 4 other locations · NCT06824155

• HF50 for HER2-positive and HER2-low advanced solid tumors

  This trial tests HF50 in adults with HER2-positive or HER2-low advanced solid tumors to find a safe dose and look for early signs it works.

  Recruiting Early Phase 1 HighField Biopharmaceuticals Corporation · Chengdu, Sichuan · NCT06822998

• DT-7012 alone and with an immune checkpoint blocker for adults with selected advanced solid tumors

  This study tests whether DT-7012, given alone or with an immune checkpoint blocker, is safe and can help adults with selected advanced solid tumors that have progressed after prior treatment.

  Recruiting at 8 sites Phase 1/2 Domain Therapeutics SA · Scottsdale, Arizona and 8 other locations · NCT06819735

• Evaluating MK-3120 for advanced solid tumors

  This study is testing a new treatment called MK-3120 to see if it can help people with advanced solid tumors that can't be removed by surgery.

  Recruiting at 28 sites Phase 1/2 Merck Sharp & Dohme LLC · Birmingham, Alabama and 48 other locations · NCT06818643

• Evaluating a new treatment for advanced solid tumors

  This study is testing a new treatment called VVD-159642 for people with advanced solid tumors to see if it is safe and how well it works, both on its own and with other therapies.

  Recruiting at 9 sites Phase 1 Vividion Therapeutics, Inc. · Grand Rapids, Michigan and 8 other locations · NCT06804824

• Assessing a new treatment for advanced solid tumors

  This study is testing a new drug called CD-001 to see if it can help people with advanced solid tumors who haven't had success with other treatments.

  Recruiting Phase 1 CD (Suzhou) Biopharma Co., Ltd. · Tianjin · NCT06801470

• Testing XNW28012 in patients with advanced solid tumors who have not responded to standard treatments

  This study is testing a new treatment called XNW28012 in patients with advanced solid tumors who haven't had success with regular cancer therapies to see if it can help them.

  Recruiting at 24 sites Phase 1/2 Evopoint Biosciences Inc. · Hefei, Anhui and 23 other locations · NCT06799637

• Testing ATX-295 for advanced solid tumors and ovarian cancer

  This study is testing a new oral medication called ATX-295 to see if it is safe and effective for people with advanced solid tumors, including ovarian cancer.

  Recruiting at 11 sites Phase 1/2 Accent Therapeutics · Aurora, Colorado and 10 other locations · NCT06799065

• Go Wish Game to support advance care planning for adults with cancer or blood cancers

  This project tries the Go Wish Game to help adults with refractory leukemia, lymphoma, multiple myeloma, or advanced solid tumors and their caregivers have end-of-life conversations and complete advance care planning.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Reggio Emilia · NCT06795815

• Combining PYX-201 with Pembrolizumab for Advanced Solid Tumors

  This study is testing a new combination of two cancer treatments, PYX-201 and pembrolizumab, to see how well they work and how safe they are for people with advanced solid tumors like certain types of breast and head and neck cancers.

  Recruiting at 22 sites Phase 1/2 Pyxis Oncology, Inc · San Diego, California and 21 other locations · NCT06795412

• Evaluating SIM0505 for advanced solid tumors

  This study is testing a new treatment called SIM0505 to see if it is safe and effective for adults with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 6 sites Phase 1 NextCure, Inc. · Orlando, Florida and 16 other locations · NCT06792552

• Evaluating AMT-116 for advanced solid tumors

  This study is testing a new treatment called AMT-116 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 6 sites Phase 1/2 Multitude Therapeutics Inc. · Fuzhou, Fujian and 6 other locations · NCT06782334

• NK042 cell injection for advanced solid tumors

  This study is testing a new cell injection called NK042 to see if it can safely help people with advanced solid tumors.

  Recruiting Phase 1 Shanghai NK Cell Technology Co., LTD · Beijing · NCT06773091

• Evaluating ODC-IL2 for advanced or metastatic solid tumors

  This study is testing a new treatment called ODC-IL2 to see if it is safe and can help adults with advanced or metastatic solid tumors.

  Recruiting Phase 1 Trutino Biosciences Inc. · Scottsdale, Arizona · NCT06770764

• Evaluating the safety and tolerability of HRS-3802 in patients with advanced solid tumors

  This study is testing a new drug called HRS-3802 to see if it is safe and tolerable for people with advanced solid tumors who haven't had success with other treatments.

  Recruiting Phase 1 Shandong Suncadia Medicine Co., Ltd. · Saint Leonards, New South Wales and 5 other locations · NCT06770569

• Combination therapy for advanced solid tumors

  This study is testing a new combination treatment for people with advanced solid tumors, including triple-negative breast cancer and liver cancer, to see if it works better after other treatments have not helped.

  Recruiting Phase 1 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · Shanghai, Shanghai Municipality · NCT06764836

• Treatment for solid tumors with HER2 mutations using BAY2927088 tablets

  This study is testing if BAY2927088 tablets can help people with advanced solid tumors that have HER2 gene mutations feel better and manage their cancer.

  Recruiting at 33 sites Phase 2 Bayer · Birmingham, Alabama and 53 other locations · NCT06760819

• Testing CS2009 for advanced solid tumors

  This study is testing a new drug called CS2009 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 32 sites Phase 1/2 CStone Pharmaceuticals · Los Angeles, California and 32 other locations · NCT06741644

• Testing SIGX1094R for advanced solid tumors

  This study is testing a new drug called SIGX1094R to see if it can help people with advanced solid tumors and to find the best dose to use.

  Recruiting Phase 1 Signet Therapeutics · Beijing · NCT06739291

• Testing SNV4818 for advanced solid tumors

  This study is testing a new medication called SNV4818 to see if it can safely help people with advanced solid tumors that have a specific genetic mutation.

  Recruiting at 12 sites Phase 1/2 Pikavation Therapeutics, Inc. · Los Angeles, California and 11 other locations · NCT06736704

• Evaluating SKB500 for advanced solid tumors

  This study is testing a new treatment called SKB500 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting Phase 1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Jilin City · NCT06736327

• Evaluating MK-6204 for advanced solid tumors

  This study is testing a new drug called MK-6204 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 8 sites Phase 1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Xiamen, Fujian and 9 other locations · NCT06726369

• Testing MGC028 in patients with advanced solid tumors

  This study is testing a new treatment called MGC028 to see if it is safe and can help adults with advanced solid tumors that can't be removed or have spread.

  Recruiting at 7 sites Phase 1 MacroGenics · San Francisco, California and 6 other locations · NCT06723236

• Testing M3T01 alone and with pembrolizumab or standard chemotherapies for advanced solid tumors

  This trial tests whether the antibody M3T01, by itself or with pembrolizumab or standard chemotherapies, is safe and might help adults with metastatic or unresectable solid tumors.

  Recruiting Phase 1 Providence Health & Services · Portland, Oregon · NCT06719362

• Using SHR-1826 with other treatments for advanced solid tumors

  This study is testing if a new treatment called SHR-1826, used with other cancer therapies, can help people with advanced solid tumors feel better and manage their disease.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT06703177

• Testing BMS-986482 for advanced solid tumors

  This study is testing a new treatment called BMS-986482, alone and with other therapies, to see if it can help people with advanced solid tumors who haven't had success with other treatments.

  Recruiting at 20 sites Phase 1/2 Bristol-Myers Squibb · Irvine, California and 20 other locations · NCT06697197

• FID-022 treatment for advanced solid tumors

  This study will test whether IV FID-022 is safe and tolerable in adults with advanced solid tumors who have no standard curative options.

  Recruiting at 3 sites Phase 1 Fulgent Pharma LLC. · Duarte, California and 2 other locations · NCT06694480

• Evaluating SIM0508 for advanced solid tumors

  This study is testing a new treatment called SIM0508, alone and with another drug, to see if it can help people with advanced ovarian, prostate, breast, or pancreatic cancers.

  Recruiting at 2 sites Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT06686745

• Testing TUB-030 for advanced solid tumors

  This study is testing a new drug called TUB-030 to see if it can safely help adults with advanced solid tumors, especially those with head and neck cancer or non-small cell lung cancer.

  Recruiting at 19 sites Phase 1/2 Gilead Sciences · New Haven, Connecticut and 19 other locations · NCT06657222

• Evaluating ALK201 for advanced solid tumors

  This study is testing a new drug called ALK201 to see if it is safe and effective for adults with advanced solid tumors.

  Recruiting at 38 sites Phase 1/2 Shanghai Allink Biotherapeutics Co., Ltd. · Denver, Colorado and 37 other locations · NCT06656390

• Evaluating SHR-3276 for patients with advanced malignant tumors

  This study is testing a new treatment called SHR-3276 to see if it can help people with advanced solid tumors who have run out of other treatment options.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Chongqing, Chongqing Municipality · NCT06643754

• Evaluating SHR-3821 injection for advanced solid tumors

  This study is testing a new injection called SHR-3821 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Chengdu, Sichuan · NCT06618651

• Evaluating HDM2005 for patients with relapsed B-cell lymphoma and advanced solid tumors

  This study is testing a new drug called HDM2005 to see if it can help people with relapsed B-cell lymphoma and advanced solid tumors feel better.

  Recruiting at 4 sites Phase 1 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Zhengzhou, Henan and 7 other locations · NCT06615193

• Evaluating SHR-7787 Injection for Advanced Solid Tumors

  This study is testing a new injection called SHR-7787 to see if it is safe and effective for people with advanced solid tumors that can't be removed by surgery.

  Recruiting Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06605222

• HRS-4508 as a first-in-human treatment in advanced solid tumors

  This study tests whether HRS-4508 can be safely given and show early signs of benefit in adults with advanced or metastatic solid tumors who have exhausted standard treatments.

  Recruiting Phase 1 Jiangsu HengRui Medicine Co., Ltd. · Beijing, Beijing Municipality · NCT06598735

• Evaluating BG-C477 for advanced solid tumors

  This study is testing a new drug called BG-C477 to see if it can safely help people with advanced solid tumors feel better and fight their cancer, both on its own and with other treatments.

  Recruiting at 59 sites Phase 1 BeOne Medicines · Goodyear, Arizona and 58 other locations · NCT06596473

• Evaluating HRS-6209 with other treatments for advanced breast cancer

  This study is testing a new drug called HRS-6209 combined with other treatments to see if it helps women with advanced breast cancer that hasn’t responded to previous therapies.

  Recruiting Phase 1/2 Jiangsu HengRui Medicine Co., Ltd. · Shanghai, Shanghai Municipality · NCT06555068

Showing recruiting studies first, then the newest. Describe your situation to find the ones that fit you.

Related topics

Quick answers

How many Advanced Solid Tumors clinical trials are recruiting right now?

205, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 43 countries. The most sites are in China (136 trials), United States (80 trials), Australia (28 trials), Spain (21 trials), Canada (16 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 112, Phase 1/2: 68, Phase 2: 10, Early Phase 1: 9. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →